IMSI vs ICSI,   IMSI並無法明顯提高懷孕率
implantation (12 vs 10 %), clinical pregnancy (23 vs 21 %), or live birth rates (20 vs 19 %).

J Assist Reprod Genet. 2016 Mar;33(3):349-55. doi: 10.1007/s10815-015-0645-5. Epub 2016 Jan 11.

Intracytoplasmic morphologically selected sperm injection (IMSI) does not improve outcome in patients with two successive IVF-ICSI failures.

Gatimel N1,2, Parinaud J3,4, Leandri RD3,4.

Author information

Abstract

PURPOSE:

Assessment of sperm morphology has been reconsidered since 2001 with the development of motile sperm organelle morphology examination (MSOME). This observation technique that combines high magnification microscopy and the Nomarski interference contrast makes it possible to select spermatozoa with as few vacuoles as possible before microinjection into the oocyte (intracytoplasmic morphologically selected sperm injection, IMSI). More than 10 years after the development of IMSI, the indications of the IMSI technique and its ability to increase pregnancy and/or birthrates (compared with conventional ICSI) are still subject to debate. We aimed to better define the interest of IMSI in the third attempt.

METHODS:

We assessed the benefit of IMSI by carrying out a retrospective comparative study between IMSI and conventional ICSI during a third ART attempt. Two hundred sixteen couples with two previous ICSI failures were studied between February 2010 and June 2014.

RESULTS:

IMSI did not significantly improve the clinical outcomes compared with ICSI, either for implantation (12 vs 10 %), clinical pregnancy (23 vs 21 %), or live birth rates (20 vs 19 %).

CONCLUSION:

This study provides supplementary arguments for not achieving IMSI procedure in the third attempt after two previous ICSI failures.